Enovis Corporation (NYSE:ENOV) is one of the 10 Best Medical Stocks to Buy Under $30. On April 17, William Blair initiated ...

On April 17, 2026, William Blair initiated coverage on Enovis Corporation (NYSE: ENOV) with an Outperform rating, emphasizing valuation opportunities and management’s guidance for free cash flow ...

JMP Securities initiated coverage on Enovis Corporation (NYSE:ENOV), a medical technology company focusing on orthopedics. The analyst adds that the company sells a broad portfolio of products, many ...

In the latest quarter, 4 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a ...

Enovis' first-quarter net sales of $559 million grew 8% on a reported basis and 9% (+10% xFX) on a comparable basis from the same quarter in 2024. First quarter results reflect continued execution in ...

Alongside an evidence-based portfolio, Enovis will showcase how it's "Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to ...

Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its ...

Enovis Corporation announced it will hold an investor conference call and live webcast to discuss its first quarter 2025 financial results on May 8, 2025, at 8:30 a.m. Eastern Time, with an earnings ...

If you date Enovis’s origin back to Colfax’s acquisition of DJO Global in 1978, the company has now been around for more than 40 years. While the medtech leader has deep roots in the world of ...